Vol. 6 No. 10 (2026): October
Reimbursement Reviews

Anifrolumab (Saphnelo)

decorative image of the issue cover

Published October 20, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses anifrolumab (SAPHNELO), 120 mg in 0.8mL, solution for injection, sub-cutaneous.
  • Indication: Is indicated in addition to standard therapy for the treatment of adult patients with active, autoantibody positive, systemic lupus erythematosus (SLE).